Algert Global LLC Has $6.13 Million Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Algert Global LLC increased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 119.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,048 shares of the company’s stock after buying an additional 21,223 shares during the period. Algert Global LLC owned 0.12% of TransMedics Group worth $6,131,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in TMDX. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at about $47,000. USA Financial Formulas acquired a new stake in shares of TransMedics Group in the 3rd quarter valued at about $55,000. J.Safra Asset Management Corp grew its stake in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the period. Signaturefd LLC grew its stake in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is owned by company insiders.

TransMedics Group Price Performance

TransMedics Group stock opened at $76.04 on Friday. TransMedics Group, Inc. has a 52 week low of $67.77 and a 52 week high of $177.37. The company’s 50 day moving average price is $119.18 and its two-hundred day moving average price is $137.70. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.55 billion, a P/E ratio of 80.89 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.12) EPS. On average, equities analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on TMDX shares. Stephens raised their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday. Piper Sandler dropped their price target on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday. Needham & Company LLC reaffirmed a “hold” rating and issued a $109.00 price target on shares of TransMedics Group in a research report on Friday. Finally, Oppenheimer dropped their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.